VAISHALI PHARMA LIMITED (VAISHALI) financials

VAISHALI PHARMA LIMITED (VAISHALI) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1989, Vaishali Pharma Ltddoes marketing of pharmaceutical products including active pharmaceutical ingredients[1]

Market Cap: ₹105Cr.
Current Price: ₹7.81
Stock P/E: 24.9
ROE: 6.02%
ROCE: 8.93%
Book Value: ₹5.29
Dividend Yield: 0.00%
52W High / Low: ₹11.2/4.75

In Jun 2026, VAISHALI PHARMA LIMITED (VAISHALI) reported sales ₹22.89 Cr and net profit ₹1.49 Cr.

Annual TTM: sales ₹108 Cr, net profit ₹4 Cr.

Shareholding: Promoters 30.54% (Jul 2026), Public 69.46% (Jul 2026), No. of Shareholders 26,697% (Jul 2026).

VAISHALI quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	20.79	27.91	32.25	23.75	33.45	24.65	26.93	22.89
Expenses	18.37	26.55	38.29	22.38	32.06	23.09	27.13	21.40
Operating Profit	2.42	1.36	-6.04	1.37	1.39	1.56	-0.20	1.49
OPM %	11.64%	4.87%	-18.73%	5.77%	4.16%	6.33%	-0.74%	6.51%
Other Income	0.71	1.07	1.00	0.84	0.84	0.89	1.26	0.58
Interest	0.38	0.38	0.44	0.33	0.40	0.51	0.72	0.20
Depreciation	0.12	0.12	0.12	0.14	0.17	0.13	0.16	0.14
Profit before tax	2.63	1.93	-5.60	1.74	1.66	1.81	0.18	1.73
Tax %	25.10%	24.87%	-23.39%	26.44%	28.31%	28.18%	-50.00%	13.87%
Net Profit	1.97	1.44	-4.29	1.28	1.18	1.30	0.27	1.49
EPS in Rs	0.18	0.13	-0.40	0.12	0.09	0.10	0.02	0.11
Raw PDF	—	—	—	—	—	—	—	—

VAISHALI profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	60	54	76	70	86	99	109	108
Expenses	59	51	69	60	85	98	105	104
Operating Profit	1	3	7	9	2	1	4	4
OPM %	1.5%	4.9%	9%	13%	1.9%	0.6%	3.8%	3.9%
Other Income	2	2	2	2	2	3	4	4
Interest	3	3	2	2	2	2	2	2
Depreciation	0	0	0	0	1	0	1	1
Profit before tax	0	1	6	9	1	1	5	5
Tax %	62%	26%	30%	25%	23%	34%	25%	—
Net Profit	0	1	4	7	1	1	4	4
EPS in Rs	0.00	0.10	0.38	0.63	0.07	0.08	0.31	0.32
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	—

VAISHALI balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	7	11	11	11	11	11	26	26
Reserves	15	11	12	16	30	32	39	43
Borrowings	17	17	18	21	15	13	12	19
Other Liabilities	30	28	46	34	24	24	33	35
Total Liabilities	69	66	86	82	79	80	110	123
Fixed Assets	1	1	1	1	2	2	2	2
CWIP	0	0	0	0	1	1	0	0
Investments	0	0	0	0	0	0	0	5
Other Assets	67	64	84	80	76	77	107	116
Total Assets	69	66	86	82	79	80	110	123

VAISHALI cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	4	3	2	1	1	1	-18	0
Cash from Investing Activity	-0	-0	-0	-1	0	1	-0	-5
Cash from Financing Activity	-4	-3	-2	0	-2	-1	18	5
Net Cash Flow	0	0	0	1	-0	1	0	-0
Free Cash Flow	4	3	2	0	1	1	-18	-0
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	212%	433%	78%	31%	28%	185%	-3,104%	19%

VAISHALI shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Jul 2026
Promoters	26.32%	26.32%	26.32%	26.32%	31.61%	31.61%	31.61%	30.54%
Public	73.68%	73.68%	73.68%	73.68%	68.39%	68.39%	68.39%	69.46%
No. of Shareholders	27,546	28,874	28,682	27,752	27,148	26,534	26,671	26,697

VAISHALI key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	240	286	453	282	281	209	172	170
Inventory Days	5	6	5	4	20	2	20	13
Days Payable	130	169	321	163	120	95	116	81
Cash Conversion Cycle	115	123	137	122	181	116	77	102
Working Capital Days	98	124	146	111	208	169	231	212
ROCE %	10%	7%	10%	19%	22%	6%	5%	9%

VAISHALIUpdated 18 Oct 2026, 0:39

Vaishali Pharma Limited

VAISHALIUpdated 18 Oct 2026, 0:39

Market Cap

₹105Cr.

Current Price

₹7.81

High / Low

₹11.2/4.75

Stock P/E

24.9

ROE6.02%

ROCE8.93%

Book Value₹5.29

Face Value₹2.00

Dividend Yield0.00%

About

Incorporated in 1989, Vaishali Pharma Ltddoes marketing of pharmaceutical products including active pharmaceutical ingredients[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	13.42	0.43	11.11	0.36	0.12	2.12	25	1.59	0.15
Sep 2023	12.57	0.47	9.92	0.3	0.12	2.36	27.97	1.7	0.16
Dec 2023	27.9	0.43	24.95	0.47	0.12	2.87	26.13	2.11	0.2
Mar 2024	32.4	0.4	39.19	0.91	0.14	-6.42	-26.95	-4.68	-0.44
Jun 2024	18.08	0.38	15.73	0.42	0.12	2.27	25.11	1.7	0.16
Sep 2024	20.79	0.38	18.37	0.71	0.12	2.63	25.1	1.97	0.18
Dec 2024	27.91	0.38	26.55	1.07	0.12	1.93	24.87	1.44	0.13
Mar 2025	32.25	0.44	38.29	1	0.12	-5.6	-23.39	-4.29	-0.4
Jun 2025	23.75	0.33	22.38	0.84	0.14	1.74	26.44	1.28	0.12
Sep 2025	33.45	0.4	32.06	0.84	0.17	1.66	28.31	1.18	0.09
Dec 2025	24.65	0.51	23.09	0.89	0.13	1.81	28.18	1.3	0.1
Mar 2026	26.93	0.72	27.13	1.26	0.16	0.18	-50	0.27	0.02
Jun 2026	22.89	0.2	21.4	0.58	0.14	1.73	13.87	1.49	0.11

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	95	3	95	4	0	0	-7	0	0.03
Mar 2016	67	3	66	3	0	0	300	0	-0.01
Mar 2017	64	3	60	1	0	1	32	1	0.15
Mar 2018	68	3	65	2	0	1	41	1	0.08
Mar 2019	75	3	73	2	0	1	37	1	0.07
Mar 2020	60	3	59	2	0	0	62	0	0
Mar 2021	54	3	51	2	0	1	26	1	0.1
Mar 2022	76	2	69	2	0	6	30	4	0.38
Mar 2023	70	2	60	2	0	9	25	7	0.63
Mar 2024	86	2	85	2	1	1	23	1	0.07
Mar 2025	99	2	98	3	0	1	34	1	0.08
Mar 2026	109	2	105	4	1	5	25	4	0.31
TTM	108	2	104	4	1	5	—	4	0.32

Shareholding pattern

As of Jul 2026%

Holder	Share
Promoters	30.54%
Public	69.46%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	Public
Dec 2023	26.62%	—	73.38%
Mar 2024	26.32%	—	73.68%
Jun 2024	26.32%	—	73.68%
Sep 2024	26.32%	—	73.67%
Dec 2024	26.32%	—	73.68%
Mar 2025	26.32%	—	73.68%
Jun 2025	26.32%	—	73.68%
Sep 2025	26.32%	—	73.68%
Dec 2025	31.61%	—	68.39%
Mar 2026	31.61%	—	68.39%
Jun 2026	31.61%	—	68.39%
Jul 2026	30.54%	—	69.46%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	0.5	3	25	17	46	2	0	0	44	46
Mar 2016	0.5	3	21	25	49	1	0	0	48	49
Mar 2017	3	1	23	18	45	1	0	0	43	45
Mar 2018	7	14	18	25	64	1	0	0	62	64
Mar 2019	7	15	17	30	69	1	0	0	67	69
Mar 2020	11	11	17	28	66	1	0	0	64	66
Mar 2021	11	12	18	46	86	1	0	0	84	86
Mar 2022	11	16	21	34	82	1	0	0	80	82
Mar 2023	11	30	15	24	79	2	1	0	76	79
Mar 2024	11	32	13	24	80	2	1	0	77	80
Mar 2025	26	39	12	33	110	2	0	0	107	110
Mar 2026	26	43	19	35	123	2	0	5	116	123

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	-4	2	2	0
Mar 2016	5	3	-8	0
Mar 2017	0	1	-1	0
Mar 2018	-9	1	8	0
Mar 2019	4	0	-4	0
Mar 2020	3	0	-3	0
Mar 2021	2	0	-2	0
Mar 2022	1	-1	0	1
Mar 2023	1	0	-2	0
Mar 2024	1	1	-1	1
Mar 2025	-18	0	18	0
Mar 2026	0	-5	5	0

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	133	221	214	240	240	286	453	282	281	209	172	170
Inventory Days	13	20	7	11	5	6	5	4	20	2	20	13
Days Payable	66	145	100	136	130	169	321	163	120	95	116	81
Cash Conversion Cycle	80	96	121	115	115	123	137	122	181	116	77	102
Working Capital Days	98	25	14	97	98	124	146	111	208	169	231	212
ROCE %	14%	13%	16%	13%	10%	7%	10%	19%	22%	6%	5%	9%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of VAISHALI PHARMA LIMITED (VAISHALI)?

The reported market capitalisation for VAISHALI PHARMA LIMITED (VAISHALI) is ₹105Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of VAISHALI?

The current price shown for VAISHALI PHARMA LIMITED (VAISHALI) on Fincrux is ₹7.81 with a 52-week high/low of ₹11.2/4.75.

What is the P/E ratio of VAISHALI PHARMA LIMITED (VAISHALI)?

The stock P/E for VAISHALI PHARMA LIMITED (VAISHALI) is 24.9 on Fincrux, with ROE at 6.02% and ROCE at 8.93%.

What were VAISHALI latest quarterly results?

For Jun 2026, VAISHALI PHARMA LIMITED (VAISHALI) reported sales ₹22.89 Cr and net profit ₹1.49 Cr (figures in ₹ crore unless noted).

What are VAISHALI annual sales and net profit?

For TTM, VAISHALI PHARMA LIMITED (VAISHALI) shows sales of ₹108 Cr and net profit of ₹4 Cr on the Fincrux profit & loss statement.

Who owns VAISHALI PHARMA LIMITED (VAISHALI)?

Latest shareholding for VAISHALI PHARMA LIMITED (VAISHALI) on Fincrux: Promoters 30.54% (Jul 2026), Public 69.46% (Jul 2026), No. of Shareholders 26,697% (Jul 2026).

Where can I find VAISHALI PHARMA LIMITED (VAISHALI) financials?

VAISHALI PHARMA LIMITED (VAISHALI) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show VAISHALI balance sheet and cash flow?

Yes. The VAISHALI PHARMA LIMITED (VAISHALI) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 18 October 2026 at 0:39